EU's CHMP endorses Pfizer-BioNTech's Omicron-adapted COVID-19 vaccine for ages 6 months and up.
Pfizer and BioNTech's Omicron KP.2-adapted COVID-19 vaccine received a positive opinion from the EU's CHMP, paving the way for authorization for individuals aged 6 months and older. This vaccine shows enhanced effectiveness against various Omicron JN.1 sublineages. Following EU approval, doses will be distributed to member states based on their orders. In the U.S., the vaccine is approved for those 12 and older, with emergency use authorization for younger children.
September 20, 2024
10 Articles